DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure

Prostate

Volumn 36, Issue 4, 1998, Pages 244-249

  Borre, Michael ^a,b   Høyer, Morten ^b   Nerstrøm, Benni ^b   Overgaard, Jens ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

DNA ploidy; Flow cytometry; Histopathological grade; Prognostic parameters; Prostatic adenocarcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; DNA DETERMINATION; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PLOIDY; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; DIPLOIDY; DNA, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; PLOIDIES; POLYPLOIDY; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0031841144     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980901)36:4<244::AID-PROS5>3.0.CO;2-F     Document Type: Article

References (38)

1. Wingo P-A, Tong T, Bolden S: Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30.
2. Engeland A, Haldorsen T, Hakulinen T, Hörte LG, Luostarinen T, Magnus K, Schou G, Sigvaldsson H, Storm HH, Tulinius H, Vaittinen P: Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. APMIS 1993;38:64-66.
3. Engeland A, Haldorsen T, Hakulinen T, Hörte LG, Luostarinen T, Schou G, Sigvaldsson H, Storm HH, Tulinius H, Vaittinen P: Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010. APMIS 1995;49:84-86.
4. Aus G, Hugosson J, Norlén L: Longterm survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995; 154:460-465.
5. Borre M, Nerstrøm B, Overgaard J: The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer 1997;80:917-928.
6. Dhom G: Epidemiological aspects of latent and clinically manifest carcinoma of the prostate. J Cancer Res Clin Oncol 1983; 106:210-218.
7. Cardino PT: Early detection of prostate cancer. Hum Pathol 1992;23:211-222.
8. Lee SE, Currin SM, Paulson DF, Walther PJ: Flow cytometric determination of ploidy in prostatic adenocarcinoma: A comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence. J Urol 1988;140: 769-774.
9. Adolfsson J, Rönström L, Hedlund P-O, Löwhagen T, Carstensen J, Tribukait B: The prognostic value of modal deoxyribonucleic acid in low grade, low stage untreated prostate cancer. J Urol 1990;144:1404-1407.
10. Badalament RA, O'Toole RV, Young DC, Drago JR: DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer. Cancer 1991;67:3014-3023.
11. Nielsen K, Overgaard J, Bentzen SM, Bruun E: Histological grade, DNA ploidy and mean nuclear volume as prognostic factors in prostatic cancer. APMIS 1993;101:614-620.
12. Blatstein LM, Ginsberg PC, Daskal I, Finkelstein LH: Flow cytometric determination of ploidy in prostatic adenocarcinoma and its relation to clinical outcome. J Am Osteopath Assoc 1993; 93:463-472.
13. Pollack A, Zagars GK, El-Naggar AK, Gauwitz MD, Terry NHA: Near-diploidy: A new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy. Cancer 1994;73:1895-1903.
14. Pindur A, Chakraborty S, Welch DG, Wheeler TM: DNA ploidy measurements in prostate cancer: Differences between image analysis and flow cytometry and clinical implications. Prostate 1994;25:189-198.
15. Di Silvo F, Eramo GD, Buscarini M, Sciarra A, Casale P, Di Nicola S, Loreto A, Seccareccia F, De Vita R: DNA ploidy, Gleason score, pathological stage and serum PSA levels as predictors of disease-free survival in C-D1 prostatic cancer patients submitted to radical retropubic prostatectomy. Eur Urol 1996;30: 316-321.
16. Greene DR, Rogers E, Wessels EC, Wheeler TM, Taylor SR, Santucci RA, Thompson TC, Scardino PT: Some small prostate cancers are nondiploid by nuclear image analysis: Correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol 1994;151:1301-1307.
17. Carmichael MJ, Veltri RW, Partin AW, Miller MC, Walch PC, Epstein JI: Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 1995;153:1015-1019.
18. Fosslund G, Nilsson B, Zetterberg A: Near tetraploid prostate carcinoma. Methodologic and prognostic aspects. Cancer 1996; 78:1748-1755.
19. Pontes JE, Wajsman Z, Huben RP, Wolf RM, Englander LS: Prognostic factors in localized prostatic carcinoma. J Urol 1985; 134:1137-1139.
20. Richie AWS, Dorey F, Layfield LJ, Hannah J, Lovrekovich H, deKornion JB: Relationship of DNA content to conventional prognostic factors in clinically localised carcinoma of the prostate. Br J Urol 1988;62:254-260.
21. Jones EC, McNeal J, Bruchovsky N, de Jong G: DNA content in prostatic adenocarcinoma. A flow cytometric study of the predictive value of aneuploidy for tumor volume, percentage Gleason grade 4 and 5, lymph node metastases. Cancer 1990;66:752-757.
22. Epstein JI, Pizov G, Steinberg GD, Carter HB, Pitcock R, Armas OA, Partin A, Walsh PC: Correlation of prostate cancer nuclear deoxyribonucleic acid, size, shape and gleason grade with pathological stage at radical prostatectomy. J Urol 1992;148:87-91.
23. Shockley KF, Maatman TJ, Carothers GC, Warzynski MJ: Comparative analysis of prognostic factors in men undergoing radical prostatectomy for adenocarcinoma of the prostate, including DNA ploidy, surgical tumor stage, prostatic specific antigen, Gleason grade, and age. Prostate 1996;29:46-50.
24. Egawa S, Satoh T, Iwamura M, Aihara M, Kuwao S, Uchida T, Koshiba K: Deoxyribonucleic acid ploidy status as no basis for pathologic stage prediction in clinically resectable prostate cancer. Urology 1996;47:548-552.
25. Coetzee LJ, Layfield LJ, Hars V, Paulson DF: Proliferative index determination in prostatic carcinoma tissue: Is there any additional prognostic value greater than that of Gleason score, ploidy and pathological stage? J Urol 1997;157;214-218.
26. Borre M, Bendtzen SM, Nerstrøm B, Overgaard J: Tumor cell proliferation and survival of patients with prostate cancer followed expectantly. J Urol 1998;159:1609-1614.
27. Hermanek P, Sobin LH, eds: "UICC TNM Classification of Malignant Tumours," 4th Ed, 2nd rev, Berlin: Springer-Verlag, 1992.
28. Mostofi FK, Sesterherm IA, Sobin LH: "Histological Typing of Prostate Tumours." Geneva: World Health Organization, 1980.
29. Hedley DW, Rugg CA, Ng ABP, Taylor IW: Influence of cellular DNA content on disease-free survival of stage II breast cancer patients. Cancer Res 1984;44:5395-5398.
30. Vendeløv LL, Christensen IJ: A review of techniques and results obtained in one laboratory by an integrated system designed for routine clinical flow cytometric DNA analysis. Cytometry 1990; 11:753-770.
31. Borre M, Nerstrøm B, Overgaard J: The dilemma of prostate cancer. A growing human and economic burden irrespective of treatment strategies. Acta Oncol 1997;36:681-687.
32. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J: Longterm survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:626-631.
33. Morrison AS: The effects of early treatment, lead time, and length bias on the mortality experienced by cases detected by screening. Int J Epidemiol 1982;11:261-267.
34. O'Malley FP, Grignon DJ, Keeney M, Kerkvliet N, McLean C: DNA heterogeneity in prostate adenocarcinoma. Cancer 1993; 71:2797-2802.
35. Greene DR, Fitzpatrick JM, Scardino PT: Anatomy of the prostate and distribution of early prostate cancer. Semin Surg Oncol 1995;11:9-22.
36. Shankey TV, Jin J-K, Dougherty S, Flanigan RC, Graham S, Pyle JM: DNA ploidy and proliferation heterogeneity in human prostate cancers. Cytometry 1995;21:30-39.
37. Grignon DJ, Sakr WA: Zonal origin of prostatic adenocarcinoma: Are there biologic differences between transition zone and peripheral zone adenocarcinomas of the prostate gland. J Cell Biochem 1994;19:267-269.
38. Adolfson J: Prognostic value of deoxyribonucleic acid content in prostatic cancer: A review of current results. Int J Cancer 1994; 58:211-216.